Hector J. Parra-Soto

Catania, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

Journal: The oncologist
Published: February 11, 2026

Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.

Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study.

Journal: Frontiers in oncology
Published: November 25, 2025

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 16, 2025

Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.

Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.

Journal: Scientific reports
Published: April 08, 2025

Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?

Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?

Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 24, 2025

Definitive (chemo)radiotherapy of enteric-type adenocarcinoma of the lung: time to unmask an underrated treatment option?

Definitive (chemo)radiotherapy of enteric-type adenocarcinoma of the lung: time to unmask an underrated treatment option?

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Published: December 29, 2024

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study.

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study.

Journal: Frontiers in oncology
Published: May 22, 2024

The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).

The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).

Journal: Tumori
Published: February 07, 2024

Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors.

Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors.

Journal: Targeted oncology
Published: November 16, 2023

Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.

Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.

Journal: Critical reviews in oncology/hematology
Published: August 16, 2023

Comparison of Quantitative Real-Time PCR and Digital PCR to Detect the Polyomavirus in Merkel Cell Carcinoma.

Comparison of Quantitative Real-Time PCR and Digital PCR to Detect the Polyomavirus in Merkel Cell Carcinoma.

Journal: Viruses
Published: September 16, 2022

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.

Journal: Journal of translational medicine
Published: July 11, 2022
Showing 1-12 of 38

Last Updated: 09/26/2026